Bɔku bɔku pipul dɛn we bin bigin fɔ tek Saxenda ɛvride de aks di sem kwɛstyɔn naw: na tɛm fɔ muf to Wegovy we dɛn kin gɛt wan tɛm ɛvri wik, ɛn aw dɛn fɔ du di swich sef wan? di tu mεdisin dεm na GLP-1 rεsεptכr agonist dεm we Novo Nordisk mek, bכt dεn de yuz difrεn mכlikul dεm (liraglutide vs semaglutide), difrεn dosin ritm dεm εn difrεn taytrayshכn schedule dεm. fכ gεt di transishכn rayt de protεkt tolerabiliti, kip weit-lכs mכmεnt εn avכyd kכmכn mistek lεk fכ כvalap di tu dεm.
If yu want fɔ luk ed-to-ed fɔ no us drɔg fit us pɔsin, si wi fɔs gayd, Fɔ Kɔmpia Wegovy ɛn Saxenda: Us Mɛrɛsin fɔ Lɔs Wɛt We Rayt fɔ Yu . Dis atikul de tɔk mɔ bɔt sɔntin we difrɛn: di prɛktikal prɔses fɔ chenj frɔm Saxenda to Wegovy, we de kɔba di tɛm, di doz fɔ stat, taytreshɔn ɛn wetin di pasɛnt ɛn klinik dɛn fɔ ɛkspɛkt insay di fɔs mɔnt.
Wetin Mek Pɔsin De Swich Frɔm Saxenda to Wegovy
Di rizin dɛn we kin mek di wan dɛn we de wok na di klinik kin tink bɔt fɔ chenj to Saxenda to Wegovy na:
Big avrej weit lɔs. Insay di STEP 8 randomized trial, big pipul dɛm we nɔ gɛt dayabitis lɔs wan min 15.8% pan bɔdi wet pan semaglutide 2.4 mg ɛvri wik versus 6.4% pan liraglutide 3.0 mg ɛvride ova 68 wik (Rubino et al., JAMA 2022).
Fɔs injɛkshɔn dɛn. Wan injεkshכn insay di wik insted fכ sεvin de mek i izi fכ adherence fכ bכku pipul dεm.
Wan ples we dɛn kɔl plateau na Saxenda. Di Saxenda lɛbl advays fɔ stɔp di tritmɛnt if big pɔsin nɔ lɔs at le 4% pan di beslayn wet afta 16 wik, we kin mek bɔku pipul dɛn we de gi mɛrɛsin fɔ rivyu ɔda tritmɛnt dɛn.
Sapɔt, kɔst ɔ inshɔrans chenj , we difrɛn bay kɔntri ɛn chenj bɔku tɛm.
Switching nɔto sɔntin we pɔsin fɔ du. US Veterans Affairs conversion guidance notes se nid nɔ de fɔ kɔnvɔyt pɔsin we de du wɛl ɛn we de lɔs in wet pan liraglutide. Di disayd fɔ bi pɔsin ɔltɛm.
Saxenda vs wegovy dosing na wan glans
Akɔdin to di ɔfishal US prɛskrib infɔmeshɔn:
Saxenda (liraglutide) ɔnda di bɔdi Dɛn kin injɛkt wan tɛm ɛvride . i de stat wit 0.6 mg pan de fכ wan wik εn i de go כp bay 0.6 mg εvri wik (1.2 mg, 1.8 mg, 2.4 mg) te di 3 mg de mεntenans dכz rich insay wik 5. di lכw doz dεm na fכ taytrayshכn nכmכ.
wegovy (semaglutide) injɛkshɔn ɔnda Dɛn kin gi di bɔdi wan tɛm insay di wik , di sem de ɛvri wik. Di eskalayshɔn schedule na:
di US lεbul we de naw de alaw bak fכ big pipul dεm we dεn tכlerεt 2.4 mg fכ at le 4 wik fכ inkrεs to maksimכm 7.2 mg evri wik we dεn klinikli indikεt fכ ridyus di wet mכr. Di doz ɛn di trɛnk we de kin difrɛn bay kɔntri, so fala di lokal lɛbl ɔltɛm. Fɔ bakgrɔn bɔt aw semaglutide de wok, rid Ɔndastand Semaglutide Injɛkshɔn ɛn aw fɔ Yuz am.
di tu lεbul dεm se di dכg nכ fכ kכmbayn wit eni כda GLP-1 rεsεptכr agonist. Dat wan lɔ de shep di wan ol swich prɔses.
Aw fɔ Swich Frɔm Saxenda to Wegovy: Step by Step
Di Wegovy ɔ di Saxenda lɛbl nɔ gɛt ɔfishal Saxenda-to-Wegovy swichin protɔkɔl. Wetin de kam biɛn de sho di klinik gayd we dɛn dɔn pablish ɛn di kɔmɔn prɔsis. Di pɔsin we de gi di mɛrɛsin kin kɔl di las kɔl ɔltɛm.
Step 1: Rivyu di Rizin fɔ di Switch
Di wan dɛn we de wok na di klinik fɔs kin kɔnfɔm wetin mek di pɔsin want fɔ chenj, ilɛksɛf na di efficacy, convenience, cost or side effects. Dɔn dɛn kin chɛk bak di tin dɛn we nɔ gri fɔ du dat. Dɛn nɔ fɔ yuz wegovy pan pasɛnt dɛn we gɛt pasɔnal ɔ famili histri bɔt mɛdula tayroyd kansa ɔ MEN 2, ɛn pipul dɛn we gɛt tayp 2 dayabitis nid fɔ wach di glukɔs we dɛn de chenj.
Step 2: Taym — Nɔ Washout Nid
Praktikal gayd we dɛn pablish insay Klinik Dayabitis (Almandoz, Lingvay ɛn Morales, 2020) sho se pɔsin we de telɛ wan de GLP-1 agonist na ful doz kin stat di wik ejen di de afta di las de doz . Nyu Ziland in Krays Chɔch Mɛdisin Infɔmeshɔn Savis (2025) sɛf tɔk se dɛn nɔ nid fɔ was. I nɔ fayn fɔ tek ɔl tu di mɛrɛsin dɛn togɛda ɔnda ɛni wan pan di lɛbl dɛn.
Wan tin de we nɔ de de. If di swich de apin bikɔs ɔf di gastrointestinal sayd ɛfɛkt, di sem gayd advays fɔ stɔp Saxenda ɛn wet te di simptom dɛn dɔn bifo yu bigin Wegovy wit in lɔs doz.
Step 3: Pik di Starting Dose
Liraglutide 3 mg daily εn semaglutide dos dεm nכ de intachεnj dεm dairekt wan, εn nכ validet ikwalεns de. Di kɔnvɛnshɔn tebul dɛn we dɛn dɔn pablish kin tek wan kɔnsavayv we:
Di pasɛnt dɛn we de tek Saxenda 0.6–1.2 mg ɛvride: dɛn kin stat Wegovy wit 0.25 mg ɛvri wik.
Di pasɛnt dɛn we de tek 1.8–2.4 mg ɛvride: 0.25 mg ɔ 0.5 mg ɛvri wik.
di pesin dεm stebul pan 3 mg evride: sכm savis dεm (VA, CMIS) de sכgεst 0.5 mg evri wik as כf-lεbul statin pכynt.
fכ stat pan 0.25 mg, lεk aw di Wegovy lεbul rεkomεnd, de stil bi di opshכn we de tek tεm pas כl εn we de alayne di lεbul.
Step 4: Escalate Ɛvri 4 Wik
frכm di stat doz, dεn de stεp Wegovy εvri 4 wik to 1.7 mg כ 2.4 mg. if dεn nכ tכlerεt wan dכz fayn, di lεbul de alaw fכ delay di nεks εskalεshכn bay 4 wik. Na di doz dɛm we yu mis, di lɛbl se if wan doz mis ɛn di nɛks wan de pas 2 dez, dɛn fɔ tek am kwik kwik wan. If yu mis tu ɔ mɔ kɔnsɛkutiv dos, i kin nid fɔ ri-ɛskal frɔm wan doz we smɔl.
Wetin fɔ Ɛkspɛkt Afta di Transishɔn
Gastrointestinal Sayd Efεkt dεm
Nɔs, dayarɛa, vɔmit ɛn kɔnstipɛshɔn na di bad bad tin dɛn we ɔl tu di mɛrɛsin dɛn kin gɛt. Insay STEP 8, di gastrointestinal ivent dεm bin ripot bay 84.1% pan di wan dεm we de yuz semaglutide εn 82.7% pan di wan dεm we de yuz liraglutide, mכst pan dεn bin mild to mכdarεt. Bɔt, smɔl patisipan dɛn bin stɔp fɔ yuz sɛmaglutayd (13.5%) pas liraglutayd (27.6%). Smɔl it, fɔ stɔp fɔ it we yu ful ɛn fɔ gɛt wata de ɛp bɔku pan di sik pipul dɛn fɔ du ɛvri nyu doz stɛp.
Trajektɔri fɔ Lɔs Wɛt
Bikɔs di Wegovy doz we dɛn bigin fɔ gi smɔl, sɔm sik pipul dɛn kin notis se dɛn kin want fɔ it smɔl bak insay di fɔs wik afta dɛn dɔn stɔp fɔ tek 3 mg Saxenda. Dis kin setul as di doz de go ɔp. Insay STEP 8, 70.9% pan di patisipan dɛm pan semaglutide ajɔst at le 10% weit lɔs, kɔmpia wit 25.6% pan liraglutide. di rizulεt stil dipכnt pan di it, aktiviti εn individyual bayoloji.
Di Chenj na di Fes ɛn di Bɔdi
we yu lכs di wet fast, dip kin sho se yu de lכs volyum na di tεmpl dεm, di chεk dεm εn di jawlayn, we dεn kכl 'Ozempic face'. Aesthetic klinik dεm de pe di wεyt-mεnejmεnt pasεnshכn dεm wit rεstכraytiv tritmεnt dεm. Wi atikul Yu tink se Dɛmal Fila kin Rivɛns Ozempik Fes? Kɔz ɛn Tritmɛnt Opshɔn dɛn de ɛksplen di opshɔn dɛm.
Kɔmɔn Mistek We Yu De Chenj Frɔm Saxenda to Wegovy
Fɔ ɔvalap di tu drɔgs dɛn. Nɔ tek di las Saxenda doz di sem de we yu tek di fɔs Wegovy injɛkshɔn.
Jomp stret to 2.4 mg. we yu skip di taytreshɔn de mek yu gɛt siriɔs GI riakshɔn ɛn di kidni injuri we gɛt fɔ du wit dɛhaydreshɔn.
Trit di dos dɛm as ikwal. 3 mg liraglutide nכ de 'di sem wit' eni patikyula semaglutide dכz.
Nɔ tek tɛm wit di mɛrɛsin fɔ dayabitis. Di wan dɛn we de tek insulin ɔ sulfonylureas kin nid fɔ ajɔst di doz fɔ mek dɛn nɔ gɛt haypoglycemia.
Yuz 'semaglutide' prodak dɛm we nɔ gɛt lɔ. Di wan dɛn we sik fɔ yuz ɔl di prɔdak dɛn we dɛn alaw, we dɛn dɔn gi dɛn frɔm di famasi dɛn we rayt.
Wetin Dis Min fɔ Klinik ɛn Distributɔ dɛn
Fɔ aesthetic ɛn wellness klinik, di rayz fɔ wik GLP-1 tɛrapi de rishep di pasɛnt joyn. Di pasɛnt dɛn we de pan mɛdikal wet mɛnejɛmɛnt kin luk fɔ tritmɛnt dɛn we de mek dɛn bɔdi kɔntɔr, we gɛt kwaliti fɔ dɛn skin ɛn we de mek dɛn volyum kam bak we dɛn de du dɛn program ɔ afta dɛn dɔn du dɛn program. Wi ɔvaviu fɔ Top Non-Surgical Body Contouring ɛn Weight Management Trends fɔ 2026 map usay di dimand de muv.
Brand ɛn distribyushɔn dɛn we de bil wan wet-mɛnejmɛnt pɔtfɔlio fɔ pe prɛskrishɔn-onli GLP-1 kia, we de ɔnda mɛdikal supavayshɔn, wit kɔmpliant adjɔnt prɔdak dɛn lɛk filɛ, kolagen stimulatɔ, mɛsotɛrapi ɛn bɔdi-kɔntɔrin injɛktabl. Fɔ ɔndastand aw prayvet-lɛbul patnaship dɛn de wok, rid Exploring OEM Weight Loss Injections: Wan Stratejik Opportunity fɔ Wɛlbɔdi ɛn Wɛlbɔdi Biznɛs . AOMA de sɔpɔt patna dɛn wit GMP-based manufakchurin, rigyuletɔri dɔkyumentri ɛn kɔstɔm branding.
FAQ we dɛn kin aks
A kin stat Wegovy di de afta mi las Saxenda injɛkshɔn?
Bɔku tɛm, na yɛs. Di gayd we dɛn dɔn pablish se dɛn nɔ nid fɔ was, ɛn di wik ɛjɛn kin bigin di de afta di las doz fɔ di de. If yu de chenj bikɔs ɔf di sayd ɛfɛkt dɛm, di pɔsin we de gi yu mɛrɛsin kin aks yu fɔ wet te di sik dɔn sɛtul.
Us Wegovy doz a fɔ stat wit afta Saxenda 3 mg?
di Wegovy lεbul de stat כlman wit 0.25 mg evri wik. Sɔm klinik savis dɛn kin tek 0.5 mg ɔf-lɛbul fɔ pasɛnt dɛn we stebul pan Saxenda 3 mg. Di pɔsin we de gi yu mɛrɛsin de disayd bay aw yu de bia wit am.
A kin tek Saxenda ɛn Wegovy togɛda?
nכ, di tu lεbul dεm se fכ kכmbayn dεm wit eni כda GLP-1 rεsεptכr agonist nכ i fayn.
Aw lɔŋ i kin tek fɔ rich di ful Wegovy doz?
frכm 0.25 mg, fכ rich 2.4 mg de tek 16 wik, wit mεntenans frכm wik 17. fכ stat pan 0.5 mg i de sכt dis bay lεk 4 wik.
Wegovy de wok fayn pas Saxenda?
Insay di STEP 8 ed-to-hed trayal, semaglutide 2.4 mg prodyuz avrej 15.8% weit lכs vεrs 6.4% wit liraglutide 3.0 mg na 68 wik. Di tin dɛn we kin apin to wan wan pɔsin kin difrɛn.
Mɛdikal Disklɛmayshɔn
Dis atikul na fɔ jenɛral ɛdyukeshɔn ɛn fɔ di wan dɛn we sabi bɔt wɛlbɔdi biznɛs ɛn di industri. I nɔto advays we dɔktɔ gi. Saxenda ɛn Wegovy na mɛrɛsin dɛn we dɛn kin gi pɔsin nɔmɔ. Ɛni chenj na di tritmɛnt, inklud di tɛm ɛn di doz, na pɔsin we gɛt laysens fɔ gi di mɛrɛsin fɔ disayd akɔdin to di lokal infɔmeshɔn bɔt di mɛrɛsin. AOMA nɔ de mek ɔ sɛl Saxenda ɔ Wegovy, we na tredmak fɔ Novo Nordisk A/S.
Rifrɛns dɛn
Rubino D. M., Grinway F. L., Khalid U., ɛn ɔda pipul dɛn. Ifekt we wik sabkutan semaglutide vs de liraglutide gɛt pan bɔdi wet pan big pipul dɛn we gɛt ɔvaweit ɔ fat we nɔ gɛt dayabitis: di STEP 8 randomized klinik trial. JAMA . 2022;327(2):138-150. PMID: 35015037, ɛn di ɔda wan dɛn.
Dr. Emily Carter (MD, Fellow of the American Academy of Dermatology) na bɔd-sɛtifiket kɔsmɛtik sajin na Nyu Yɔk Siti wit pas 9 ia spɛshal ɛkspiriɛns pan hyaluronic acid filers, akni ska tritmɛnt, ɛn minimally invasive facial contouring. Dɛn no am mɔ fɔ in ɛkspɛriɛns pan advans injɛkshɔn tritmɛnt dɛn we de mek di akni ska dɛn layt fayn fayn wan, mek di skin wɛl, ɛn mek di skin smol bak tru di injɛkshɔn we dɛn dɔn tɔk bɔt fɔ mek di skin ripɛnt ɛn di tɛknik dɛn we dɛn de yuz fɔ mek di skin go bifo.
